Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome
- PMID: 20211328
- DOI: 10.1016/j.amjcard.2009.11.042
Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome
Abstract
Adenosine and regadenoson cause an increase in heart rate (HR) during myocardial perfusion imaging (MPI). It has been shown that patients with diabetes mellitus have a blunted HR response due to cardiac autonomic dysfunction. It is not known whether the HR response is related to hyperglycemia and the metabolic syndrome (MS). HR changes were assessed in 2,000 patients (643 with diabetes mellitus [DM]) in the Adenoscan Versus Regadenoson Comparative Evaluation for Myocardial Perfusion Imaging (ADVANCE MPI 1 and ADVANCE MPI 2) trials in relation to MS status and blood sugar level on the day of MPI. The HR response was lower in patients with MS (32.43 +/- 0.52% vs 36.15 +/- 0.71%, p <0.001). An increase in the number of features of MS was associated with a stepwise decrease in the HR response (-0.92% per MS criterion, p <0.05), irrespective of the presence of DM. Increasing blood sugar levels resulted in blunting of the HR response even after controlling for DM and MS (0.60 +/- 0.08% per 10 mg/dl, p <0.001). MS was independently related to the HR response on top of DM, renal function, left ventricular function, gender, age, baseline HR, blood pressure, and beta-blocker use. The overall model was highly associated with the HR response (p <0.001) and able to explain 30% of its variation. In conclusion, the HR response to adenosine and regadenoson is blunted in patients with hyperglycemia and in those with MS. These results suggest that factors that precede the development of DM may be associated with cardiac autonomic neuropathy and may help explain the contribution of hyperglycemia and MS to cardiovascular risk.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus.Am Heart J. 2009 Apr;157(4):771-6. doi: 10.1016/j.ahj.2009.01.011. Epub 2009 Mar 6. Am Heart J. 2009. PMID: 19332209 Clinical Trial.
-
The prognostic value of the heart rate response to adenosine in relation to diabetes mellitus and chronic kidney disease.Am Heart J. 2011 Aug;162(2):356-62. doi: 10.1016/j.ahj.2011.05.014. Epub 2011 Jul 18. Am Heart J. 2011. PMID: 21835298
-
Regadenoson: a new myocardial stress agent.J Am Coll Cardiol. 2009 Sep 22;54(13):1123-30. doi: 10.1016/j.jacc.2009.04.089. J Am Coll Cardiol. 2009. PMID: 19761931 Review.
-
Regadenoson.Am J Cardiovasc Drugs. 2010;10(1):65-71. doi: 10.2165/10489040-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20063904
-
Advances in pharmacologic stress agents: focus on regadenoson.J Nucl Med Technol. 2010 Sep;38(3):163-71. doi: 10.2967/jnmt.109.065581. Epub 2010 Aug 19. J Nucl Med Technol. 2010. PMID: 20724531 Review.
Cited by
-
Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial.Int J Cardiovasc Imaging. 2013 Jun;29(5):1029-37. doi: 10.1007/s10554-012-0166-6. Epub 2012 Dec 11. Int J Cardiovasc Imaging. 2013. PMID: 23224354 Clinical Trial.
-
A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging.J Nucl Cardiol. 2011 Dec;18(6):1086-94. doi: 10.1007/s12350-011-9429-1. Epub 2011 Jul 22. J Nucl Cardiol. 2011. PMID: 21785922
-
Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.J Nucl Cardiol. 2018 Feb;25(1):137-149. doi: 10.1007/s12350-017-0960-6. Epub 2017 Jun 26. J Nucl Cardiol. 2018. PMID: 28653271 Review.
-
Safety of regadenoson in patients with end-stage liver disease.J Nucl Cardiol. 2011 Feb;18(1):90-5. doi: 10.1007/s12350-010-9288-1. Epub 2010 Sep 18. J Nucl Cardiol. 2011. PMID: 20848256 Clinical Trial.
-
Heart rate response during vasodilator stress myocardial perfusion imaging: Mechanisms and implications.J Nucl Cardiol. 2010 Aug;17(4):536-9. doi: 10.1007/s12350-010-9248-9. J Nucl Cardiol. 2010. PMID: 20506008 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical